The Magazine for Sleep Professionals
Wednesday, June 10, 2026
Similar to its prevalence in the adult population, obstructive sleep apnea (OSA) in children is one of the most common manifestations of sleep-related breathing disorders. The prevalence of OSA in children has significantly increased in the last 20 years, particularly among the younger population, possibly linked to the rise in […]
A new clinical practice guideline developed by the American Academy of Sleep Medicine provides updated recommendations for the treatment of restless legs syndrome. The guideline reflects the latest scientific evidence and recommends significant changes in the standard treatment of RLS in adults. Available online as an accepted paper in the […]
LivaNova PLC, a market-leading medical technology company, today announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with its safety endpoints, the RCT achieved statistical significance of its primary endpoint responder rates1,2 between the treatment […]
Fisher & Paykel Healthcare has announced the launch of F&P Nova MicroTM nasal pillows mask for the treatment of obstructive sleep apnea (OSA) in the USA. Weighing less than 1.4 ounces (40 grams), the new compact mask features minimal, easy-adjusting headgear and a soft MicroPillowsTM cushion that nestles gently within […]
Sleep Specialists, LLC (DBA 2Z Medical) announces that Zzoma is now covered by a growing number of leading health insurance providers. This expanded coverage significantly increases access to this innovative, mask-free treatment option for individuals with positional OSA across the United States. Zzoma is an FDA-cleared positional therapy device indicated […]
Avadel Pharmaceuticals plc announced today that the U.S. Food and Drug Administration (FDA) has approved its supplemental new drug application (sNDA) for LUMRYZ for the treatment of cataplexy or EDS in patients 7 years of age and older with narcolepsy. “This approval represents an important milestone for the narcolepsy community, […]
While continuous positive airway pressure (CPAP) is still the gold standard treatment for obstructive sleep apnea (OSA), it is well-established that many patients struggle with long-term adherence and tolerance.1 The literature indicates that CPAP non-compliance rates remain as high as 34% with little improvement over the last two decades.2 As […]
React Health has announced the latest addition to its Rio II family of masks: the Rio II Full Face Mask, which is now available. Designed to enhance patient comfort and compliance with sleep therapy, the Rio II offers a cost-competitive alternative to many leading masks on the market without compromising […]
EnsoData and Nonin partner to address the underserved and undiagnosed sleep apnea patient population with a collaborative home sleep apnea testing approach. The partnership will combine the recently FDA-cleared EnsoSleep PPG software as a medical device (SaMD) algorithm with Nonin’s WristOx2® Model 3150 reusable wrist-worn device, offering sleep labs an […]
Harmony Biosciences announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of excessive daytime sleepiness (EDS) in pediatric patients six years of age and older with narcolepsy. The FDA separated the submission into two sNDAs […]
